2. PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in pstmenopausal women with endocrine-resistant HR+/HER2- advanced breast cancer (BC): First results from the randomized, Phase III BELLE-2 trial

3. Effects of perioperative lapatinib in early HER2+ breast cancer – The UK EPHOS-B trial (CRUK/08/002)

4. High prevalence and clonal heterogeneity of ESR1 mutations (mt) in circulating tumor DNA (ctDNA) from patients (pts) enrolled in FERGI, a randomized Phase II study testing pictilisib (GDC-0914) in combination with fulvestrant (F) in pts that failed a prior aromatase inhibitor(AI)

5. A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predicts degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B31 for HER2+ breast cancer

6. P53 mutations in HER2 positive and triple negative breast cancer treated with neoadjuvant chemotherapy – A translational subproject of Gepar Sixto trial

7. Somatic BRCA 1 mutations determine different responses to platinum-based chemotherapy

8. Histology and molecular characteristics of pregnancy associated breast cancer

9. Evaluation of PDL1 expression in breast cancer by immunohistochemistry

10. Targeting unique metabolic vulnerabilities in dormant ER & plus; tumor cells

11. Smart delivery of lapatinib to reduce its cardiotoxicity: A 99mTc labeled biodistribution study

12. 230 Clinical patterns of metastatic spread from formal in fixed, paraffin-embedded (FFPE) expression profiles: A case-control study of 1,357 breast cancer patients

13. Evolution from primary breast cancer to relapse and metastasis

14. The driver landscape of breast cancer metastasis and relapse. 2015 European Cancer Congress

15. Final updated results of the NRG Oncology/ NSABP ProtocolP2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer

16. Breast MRI screening of women at average risk of breast cancer: An observational cohort study

17. Agreement in risk assessment among breast cancer specialists: A survey within the MINDACT cohort

18. Male breast cancer receptor sub-types: Demographics, tumor characteristics and short term survival outcomes

19. Examination of the sentinel lymph node identification in breast cancer combining contrast enhanced ultrasonography and the blue dye method without radioisotope

20. Association between HER2 phenotype on circulating tumor cells and primary tumor characteristics in women with metastatic breast cancer

21. Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine